A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity

被引:27
作者
Schar, Christine R. [1 ]
Blouse, Grant E. [2 ]
Minor, Kenneth H. [1 ]
Peterson, Cynthia B. [1 ]
机构
[1] Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA
[2] Univ Aarhus, Dept Mol & Struct Biol, Lab Cellular Protein Sci, DK-8000 Aarhus, Denmark
关键词
D O I
10.1074/jbc.M708017200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are important physiological binding partners that work in concert to regulate cellular adhesion, migration, and fibrinolysis. The high affinity binding site for PAI-1 is located within the N-terminal somatomedin B domain of vitronectin; however, several studies have suggested a second PAI-1-binding site within vitronectin. To investigate this secondary site, a vitronectin mutant lacking the somatomedin B domain (r Delta sBVN) was engineered. The short deletion had no effect on heparin-binding, integrin-binding, or cellular adhesion. Binding to the urokinase receptor was completely abolished while PAI-1 binding was still observed, albeit with a lower affinity. Analytical ultracentrifugation on the PAI-1-vitronectin complex demonstrated that increasing NaCl concentration favors 1:1 versus 2:1 PAI-1-vitronectin complexes and hampers formation of higher order complexes, pointing to the contribution of charge-charge interactions for PAI-1 binding to the second site. Furthermore, fluorescence resonance energy transfer between differentially labeled PAI-1 molecules confirmed that two independent molecules of PAI-1 are capable of binding to vitronectin. These results support a model for the assembly of higher order PAI-1-vitronectin complexes via two distinct binding sites in both proteins.
引用
收藏
页码:10297 / 10309
页数:13
相关论文
共 75 条
[1]   PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 - REACTIVE CENTER AND AMINO-TERMINAL HETEROGENEITY DETERMINED BY PROTEIN AND CDNA SEQUENCING [J].
ANDREASEN, PA ;
RICCIO, A ;
WELINDER, KG ;
DOUGLAS, R ;
SARTORIO, R ;
NIELSEN, LS ;
OPPENHEIMER, C ;
BLASI, F ;
DANO, K .
FEBS LETTERS, 1986, 209 (02) :213-218
[2]   KINETICS VERSUS THERMODYNAMICS IN PROTEIN-FOLDING [J].
BAKER, D ;
AGARD, DA .
BIOCHEMISTRY, 1994, 33 (24) :7505-7509
[3]   MOLECULAR EVOLUTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 FUNCTIONAL STABILITY [J].
BERKENPAS, MB ;
LAWRENCE, DA ;
GINSBURG, D .
EMBO JOURNAL, 1995, 14 (13) :2969-2977
[4]  
BITTORF SV, 1993, J BIOL CHEM, V268, P24838
[5]   PLASMIN CLEAVAGE OF VITRONECTIN - IDENTIFICATION OF THE SITE AND CONSEQUENT ATTENUATION IN BINDING PLASMINOGEN-ACTIVATOR INHIBITOR-1 [J].
CHAIN, D ;
KREIZMAN, T ;
SHAPIRA, H ;
SHALTIEL, S .
FEBS LETTERS, 1991, 285 (02) :251-256
[6]   Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins [J].
Czekay, RP ;
Aertgeerts, K ;
Curriden, SA ;
Loskutoff, DJ .
JOURNAL OF CELL BIOLOGY, 2003, 160 (05) :781-791
[7]   CHARACTERIZATION OF HUMAN S-PROTEIN, AN INHIBITOR OF THE MEMBRANE ATTACK COMPLEX OF COMPLEMENT - DEMONSTRATION OF A FREE REACTIVE THIOL-GROUP [J].
DAHLBACK, B ;
PODACK, ER .
BIOCHEMISTRY, 1985, 24 (09) :2368-2374
[8]   Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin [J].
Deng, G ;
Royle, G ;
Wang, S ;
Crain, K ;
Loskutoff, DJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (22) :12716-12723
[9]   Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? [J].
Deng, G ;
Curriden, SA ;
Wang, SJ ;
Rosenberg, S ;
Loskutoff, DJ .
JOURNAL OF CELL BIOLOGY, 1996, 134 (06) :1563-1571
[10]   The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent [J].
Devy, L ;
Blacher, S ;
Grignet-Debrus, C ;
Bajou, K ;
Masson, R ;
Gerard, RD ;
Gils, A ;
Carmeliet, G ;
Carmeliet, P ;
Declerck, PJ ;
Noël, A ;
Foidart, JM .
FASEB JOURNAL, 2002, 16 (02) :147-154